
    
      In this study, the pharmacokinetics and safety of a Novel Antiviral Drug will be determined
      in babies with neonatal HSV CNS disease. The study will be conducted at 18 academic medical
      centers throughout the United States. Young infants presenting with virologic confirmation of
      neonatal HSV infection and evidence of CNS involvement will be eligible for study enrollment.
      Study Day 1 is defined as the day when dose 1 of the Novel Antiviral Drug study medication is
      administered.
    
  